SEngine Precision Medicine

03/08/2023

Today, we announced that our is accessible to patients with in all 50 states, thanks to certification through NY State Department of Health’s rigorous CLEP. This opens new possibilities for thousands of patients suffering today who have yet to see the promise of precision medicine come to fruition.

Now, care teams across the U.S. can send a biopsy from their patients’ tumors, which we use to build 3D organoids for personalized testing of dozens of potential medicines for , helping maximize the success rate of treatment while minimizing safety issues. Learn more here.

From a single sample taken from a patient’s tumor, SEngine scientists can discover which drugs or combinations of drugs are most effective in killing or...

12/14/2022

Later today, our CEO Dr. Carla Grandori will be one of four panelists at the Puget Sound Business Journal Women Who Lead program. At this exciting event, top women leaders in life sciences and bio-tech have been brought together to talk about their path to the top, the challenges they faced along the way and where they see the industry going from here.

11/19/2022

Today is . It is important that we take today to recognize men’s mental and physical health, and how we can help to advocate for it through staying aware and being proactive in getting health screenings. Mental and physical health are both equally important, and it is imperative that we stay vigilant in helping the men in our lives get the help they may need.

11/15/2022

Here at SEngine, we have created a functional Synthetic Lethal strategy that identifies drug targets that support or promote malignancy, but that are minimally important in non-cancerous cells - leading to effective drugs with minimal side effects.

There are several difficult-to-drug oncogenes and mutated tumor suppressors that drive several different cancer types, and these drivers of malignancy serve as the basis for SEngine’s functional Synthetic Lethal screening strategy.

11/10/2022

Did you know that MYC, a well characterized driver oncogene, is amplified in 28% percent of solid tumors, but is very difficult to directly drug?

SEngine has identified several drug targets that are essential for the survival and proliferation of MYC-driven cancers - understanding how survives and grows is essential to discovering how we can fight it.
https://loom.ly/Lqs9rjU

SEngine Precision Medicine

11/08/2022

During awareness month, we would like to highlight that SEngine is conducting a Non-Small Cell Lung Cancer (NSCLC) study with the esteemed Johns Hopkins Medicine

This study utilizes SEngine’s high-throughput patient-derived organoid drug screening technology to identify novel therapeutic targets in progressive ALK+ NSCLC.

https://loom.ly/esPC2XQ

This study aims to identify novel therapeutic options for ALK+ patients that have developed resistance to first-line cancer treatment...

11/03/2022

Our PARIS for Pharma platform allows SEngine, and partners, to find the most responsive patient populations for a drug, increasing the chance of success in future . This functional assessment of drug responsiveness is superior to previous, more hypothetical, patient selection techniques. Check out our website or reach out to us to learn more!

10/25/2022

Did you know DNA sequencing alone predicts effective treatment of an estimated 15% of the time? The PARIS® Test delivers effective treatment options for solid tumors up to 80% of the time, based on recent testing. Read more about our PARIS® Test here, and reach out to care@senginemedicine.com for more information! https://loom.ly/Y084fzE

The Search Engine For Identifying Personalized Cancer Treatments.

10/21/2022

In support of , today we encourage breast cancer screenings through mammograms. Mammograms are the best way to detect breast cancer early on, when it can be easier to treat.

10/20/2022

On average, it can take anywhere from 1 week to 2 years to assess the effectiveness of 1 treatment against your cancer.

Here at SEngine, we use 1 test of up to 43 drugs against a biopsy of your cancer to tell you which drugs will work best. Let us help guide you towards the best treatment for YOU.

10/18/2022

As of 2021, breast cancer became the most common cancer globally. 1 in 8 U.S. women will develop breast cancer in their lifetime. October is our opportunity to increase awareness and visibility for those who are championing and fighting for scientific advances in prevention, screening and treatment for breast cancer.

10/12/2022

SEngine follows through on its commitment to cancer patients with its drug discovery programs - aimed at making novel, less toxic, drugs. CEO and co-founder Dr. Carla Grandori states "I am excited our drug discovery effort is advancing" as we are poised to begin 2 new drug discovery programs targeting synthetic lethal pathways.